- Home
- GNLX vs GBLI Comparison
GNLX vs GBLI Comparison
Compare GNLX & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- GBLI
- Stock Information
- Founded
- GNLX 2001
- GBLI 2016
- Country
- GNLX United States
- GBLI United States
- Employees
- GNLX N/A
- GBLI N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- GBLI Property-Casualty Insurers
- Sector
- GNLX Health Care
- GBLI Finance
- Exchange
- GNLX Nasdaq
- GBLI Nasdaq
- Market Cap
- GNLX 109.4M
- GBLI 484.5M
- IPO Year
- GNLX 2023
- GBLI 2003
- Fundamental
- Price
- GNLX $3.08
- GBLI N/A
- Analyst Decision
- GNLX Strong Buy
- GBLI
- Analyst Count
- GNLX 4
- GBLI 0
- Target Price
- GNLX $17.75
- GBLI N/A
- AVG Volume (30 Days)
- GNLX 155.2K
- GBLI 1.7K
- Earning Date
- GNLX 08-13-2025
- GBLI 08-06-2025
- Dividend Yield
- GNLX N/A
- GBLI 4.44%
- EPS Growth
- GNLX N/A
- GBLI N/A
- EPS
- GNLX N/A
- GBLI 1.99
- Revenue
- GNLX N/A
- GBLI $437,447,000.00
- Revenue This Year
- GNLX N/A
- GBLI $7.67
- Revenue Next Year
- GNLX N/A
- GBLI $7.93
- P/E Ratio
- GNLX N/A
- GBLI $15.85
- Revenue Growth
- GNLX N/A
- GBLI N/A
- 52 Week Low
- GNLX $1.60
- GBLI $26.94
- 52 Week High
- GNLX $5.89
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- GNLX 52.03
- GBLI 44.43
- Support Level
- GNLX $2.80
- GBLI $30.00
- Resistance Level
- GNLX $3.61
- GBLI $33.25
- Average True Range (ATR)
- GNLX 0.23
- GBLI 0.66
- MACD
- GNLX 0.02
- GBLI -0.24
- Stochastic Oscillator
- GNLX 38.37
- GBLI 9.75
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.